DD242349A5 - Verfahren zur herstellung einer synergistischen kombination von flupirtin und 4-acetamido-phenol - Google Patents

Verfahren zur herstellung einer synergistischen kombination von flupirtin und 4-acetamido-phenol Download PDF

Info

Publication number: DD242349A5
Authority: DD; German Democratic Republic
Prior art keywords: flupirtine; weight; phenol; physiologically acceptable; acetamido
Prior art date: 1985-06-28

Application number

DD86285896A

Other languages

German (de)

English (en)

Inventor

Carl H Weischer

Helmut Hettche

Hans-Peter Breuel

Original Assignee

��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-06-28

Filing date

1986-01-02

Publication date

1987-01-28

1986-01-02 Application filed by ��@��k�� filed Critical ��@��k��

1987-01-28 Publication of DD242349A5 publication Critical patent/DD242349A5/de

Links

JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 title claims abstract description 53
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 48
238000004519 manufacturing process Methods 0.000 title claims 3
239000011885 synergistic combination Substances 0.000 title abstract description 5
229960003667 flupirtine Drugs 0.000 claims abstract description 46
150000003839 salts Chemical class 0.000 claims abstract description 13
238000000034 method Methods 0.000 claims abstract description 11
239000002253 acid Substances 0.000 claims abstract description 8
150000007513 acids Chemical class 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims abstract description 7
239000004480 active ingredient Substances 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims abstract description 3
229910052751 metal Inorganic materials 0.000 claims abstract 5
239000002184 metal Substances 0.000 claims abstract 5
150000002739 metals Chemical class 0.000 claims abstract 5
239000000546 pharmaceutical excipient Substances 0.000 claims abstract 4
239000012050 conventional carrier Substances 0.000 claims abstract 3
239000000203 mixture Substances 0.000 claims description 7
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
229920002261 Corn starch Polymers 0.000 claims description 2
108010010803 Gelatin Proteins 0.000 claims description 2
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
229920000881 Modified starch Polymers 0.000 claims description 2
239000004368 Modified starch Substances 0.000 claims description 2
239000008120 corn starch Substances 0.000 claims description 2
229910021485 fumed silica Inorganic materials 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
239000008273 gelatin Substances 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
229940116364 hard fat Drugs 0.000 claims description 2
235000019359 magnesium stearate Nutrition 0.000 claims description 2
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
239000008108 microcrystalline cellulose Substances 0.000 claims description 2
229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
235000019426 modified starch Nutrition 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
229940083466 soybean lecithin Drugs 0.000 claims 1
230000000202 analgesic effect Effects 0.000 abstract description 11
230000002195 synergetic effect Effects 0.000 abstract description 4
230000003389 potentiating effect Effects 0.000 abstract description 3
230000001741 anti-phlogistic effect Effects 0.000 abstract description 2
239000007884 disintegrant Substances 0.000 abstract 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
229960005489 paracetamol Drugs 0.000 description 32
DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 7
208000002193 Pain Diseases 0.000 description 6
229960001655 flupirtine maleate Drugs 0.000 description 6
230000036407 pain Effects 0.000 description 6
230000000694 effects Effects 0.000 description 5
241000700159 Rattus Species 0.000 description 4
229940079593 drug Drugs 0.000 description 4
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 4
239000000829 suppository Substances 0.000 description 4
208000025747 Rheumatic disease Diseases 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000000552 rheumatic effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000008733 trauma Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
WHXDLJOHWHFXJR-UHFFFAOYSA-N CC(=O)NC1=CC=C(O)C=C1.CC(=O)NC1=CC=C(O)C=C1 Chemical compound CC(=O)NC1=CC=C(O)C=C1.CC(=O)NC1=CC=C(O)C=C1 WHXDLJOHWHFXJR-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
208000004145 Endometritis Diseases 0.000 description 1
206010022714 Intestinal ulcer Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
240000001987 Pyrus communis Species 0.000 description 1
206010049677 Salpingo-oophoritis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD86285896A 1985-06-28 1986-01-02 Verfahren zur herstellung einer synergistischen kombination von flupirtin und 4-acetamido-phenol DD242349A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3523120		1985-06-28

Publications (1)

Publication Number	Publication Date
DD242349A5 true DD242349A5 (de)	1987-01-28

Family

ID=6274416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD86285896A DD242349A5 (de)	1985-06-28	1986-01-02	Verfahren zur herstellung einer synergistischen kombination von flupirtin und 4-acetamido-phenol

Country Status (12)

Country	Link
EP (1)	EP0207193A2 (fr)
JP (1)	JPS624229A (fr)
AU (1)	AU570582B2 (fr)
DD (1)	DD242349A5 (fr)
DE (1)	DE3545201A1 (fr)
DK (1)	DK596785A (fr)
ES (1)	ES8702142A1 (fr)
FI (1)	FI855016A7 (fr)
GR (1)	GR860120B (fr)
HU (1)	HU193845B (fr)
PT (1)	PT81848B (fr)
ZA (1)	ZA859770B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN172468B (fr) *	1990-07-14	1993-08-14	Asta Medica Ag
DE4236752A1 (de) *	1992-10-30	1994-05-05	Asta Medica Ag	Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit
DE4319649A1 (de) *	1993-03-18	1994-09-22	Asta Medica Ag	Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
KR20020040767A (ko) *	1999-08-03	2002-05-30	아베데 파르마 게엠베하 운트 콤파니 카게	개와 고양이에서 퇴행성 관절 질환으로 인한 통증을경감시키기 위한 플루피르틴의 용도
EP1701725B1 (fr)	2003-12-16	2013-07-31	Relevare Aust. Pty Ltd	Compositions comprenant le flupiritne et un opioide pour le traitement de la douleur neuropathique
JP5909750B2 (ja) *	2007-11-13	2016-04-27	マリンクロットアイピー	低用量静脈内アセトアミノフェン
DE102010063612A1 (de)	2010-12-20	2012-06-21	Awd.Pharma Gmbh & Co. Kg	Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamidsäureethylester und 2-[2-[(2,6-Dichlorphenyl)-amino]-phenyl]-essigsäure
DE102010063609A1 (de)	2010-12-20	2012-06-21	Awd.Pharma Gmbh & Co. Kg	Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO860825L (no) *	1985-03-23	1986-09-24	Degussa	Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.

1985
- 1985-12-17 FI FI855016A patent/FI855016A7/fi not_active IP Right Cessation
- 1985-12-20 DK DK596785A patent/DK596785A/da not_active Application Discontinuation
- 1985-12-20 DE DE19853545201 patent/DE3545201A1/de not_active Withdrawn
- 1985-12-20 ZA ZA859770A patent/ZA859770B/xx unknown
- 1985-12-20 EP EP85116358A patent/EP0207193A2/fr not_active Withdrawn
1986
- 1986-01-02 DD DD86285896A patent/DD242349A5/de unknown
- 1986-01-06 HU HU8633A patent/HU193845B/hu unknown
- 1986-01-16 PT PT81848A patent/PT81848B/pt not_active IP Right Cessation
- 1986-01-17 GR GR860120A patent/GR860120B/el unknown
- 1986-01-21 AU AU52548/86A patent/AU570582B2/en not_active Expired - Fee Related
- 1986-01-24 JP JP61012242A patent/JPS624229A/ja active Pending
- 1986-02-03 ES ES551584A patent/ES8702142A1/es not_active Expired

Also Published As

Publication number	Publication date
FI855016L (fi)	1986-12-29
FI855016A7 (fi)	1986-12-29
DE3545201A1 (de)	1987-01-02
ES551584A0 (es)	1986-12-16
DK596785A (da)	1986-12-29
ES8702142A1 (es)	1986-12-16
EP0207193A2 (fr)	1987-01-07
GR860120B (en)	1986-05-19
HU193845B (en)	1987-12-28
JPS624229A (ja)	1987-01-10
ZA859770B (en)	1986-08-27
PT81848B (pt)	1990-11-20
PT81848A (de)	1986-02-01
AU570582B2 (en)	1988-03-17
AU5254886A (en)	1987-01-08
DK596785D0 (da)	1985-12-20
HUT40566A (en)	1987-01-28
FI855016A0 (fi)	1985-12-17

Publication	Publication Date	Title
DE3586545T2 (de)	1993-03-04	Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
EP0241809B1 (fr)	1990-08-08	Association synergétique d'amantadine et de sélégiline
DE3850434T2 (de)	1995-02-23	Arzneimittel, diätetisches Produkt und hygienisches Produkt in Form einer pulverigen Zusammensetzung, erhalten durch Adsorption der Wirkstoffe auf einem schnellöslichen Zucker und Verfahren zur Herstellung dieser Zusammensetzung.
DE19541128C2 (de)	1997-11-27	Stabilisierte schilddrüsenhormonhaltige Arzneimittel
EP1174130A2 (fr)	2002-01-23	Utilisation des préparations des plantes de curcuma
EP0248047A1 (fr)	1987-12-09	Medicament a effet anti-tumoral contenant de l'hexadecylphosphocholine.
DE2555411A1 (de)	1976-06-10	Pharmazeutische zusammensetzung mit einem n-substituierten pyridon
DD201974A5 (de)	1983-08-24	Verfahren zur herstellung von festen arzneizubereitungen enthaltend nifedipin
DE3607381A1 (de)	1987-09-10	Verwendung von diphenylhydantoin und seinen derivaten zur behandlung von immunerkrankungen
DD242349A5 (de)	1987-01-28	Verfahren zur herstellung einer synergistischen kombination von flupirtin und 4-acetamido-phenol
EP0205865B1 (fr)	1989-06-21	Préparations pharmaceutiques à effet antihypertenseur et cardioprotecteur
DE3739779A1 (de)	1989-06-08	Pharmazeutische praeparate
DE3035688C2 (fr)	1990-05-17
DE69828390T2 (de)	2005-06-02	Antikrebs-zusammensetzung
DE3116029C2 (fr)	1991-01-17
DE69630073T2 (de)	2004-06-17	(-)Hydroxycitrat enthaltende Verbindungen mit neuen therapeutischen Wirkungen
DE3141970C2 (fr)	1987-09-24
DD209735A5 (de)	1984-05-23	Verfahren zur herstellung eines neuen arzneimittelpraeparates
DE3406837C2 (fr)	1990-12-20
DE3306299C2 (fr)	1990-03-29
DE2621906C2 (fr)	1988-04-21
DE2532180C2 (de)	1986-12-18	Verwendung von Etozolin bei der Bekämpfung der Hypertonie
DE2755017A1 (de)	1978-06-29	Oral verabreichbare arzneimittel mit psychostimulierender wirkung
EP0253293A1 (fr)	1988-01-20	Sels d'un acide aspartique avec des guanidines
DE2456172C3 (de)	1977-03-17	Arzneimittel bei rheumatischen Erkrankungen